The charts on this page feature a breakdown of the total annual pay for the top executives at Blueprint Medicines Corp as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Blueprint Medicines Corp income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Blueprint Medicines Corp annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Jeffrey W. Albers
President and Chief Executive Officer
Total Cash $1,370,800 Equity $8,330,904 Other $11,600 Total Compensation $9,713,304
Michael Landsittel
Chief Financial Officer
Total Cash $667,453 Equity $2,720,511 Other $11,600 Total Compensation $3,399,564
Kathryn Haviland
Chief Operating Officer
Total Cash $774,786 Equity $2,720,511 Other $11,600 Total Compensation $3,506,897
Fouad Namouni M.D.
President, Research and Development
Total Cash $856,084 Equity $2,720,511 Other $130,437 Total Compensation $3,707,032
Percy Carter Ph.D.
Chief Scientific Officer
Total Cash $527,029 Equity $3,830,847 Other $19,650 Total Compensation $4,377,526
For its 2021 fiscal year, Blueprint Medicines Corp, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Jeffrey W. Albers CEO Pay $9,713,304 Median Employee Pay $396,068 CEO Pay Ratio 25:1
For its 2021 fiscal year, Blueprint Medicines Corp, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alexis Borisy Total Cash $443,655
Charles A. Rowland, Jr. Total Cash $467,268
Daniel S. Lynch Total Cash $156,697
Daniella Beckman Total Cash $675,938
George D. Demetri Total Cash $453,655
Lonnel Coats Total Cash $457,899
Lynn Seely, M.D. Total Cash $465,085
Mark Goldberg, M.D. Total Cash $452,982
Nicholas Lydon, Ph.D. Total Cash $472,016

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.